Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 18, 2009BloodOpen Access

KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation

View Full Paper
Ask AI
Bookmark
Share

Authors

YSYukimasa ShiotsuBridgestone (Japan)HKHitoshi KiyoiNagoya UniversityYIYuichi IshikawaNagoya University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Shiotsu et al. (2009) studied this question.

synapsesocial.com/papers/69d74ef458d71cbec648f71ehttps://doi.org/10.1182/blood-2009-01-199307
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed <i>BCR</i>-<i>ABL</i>–Positive Acute Lymphoblastic Leukemia: A Phase II Study by the Japan Adult Leukemia Study Group2005 · 454 citations
  2. 2Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia2006 · 3,514 citations
  3. 3A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease2005 · 493 citations
  4. 4Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia2003 · 275 citations
  5. 5Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications2005 · 354 citations